{"id":"levalbuterol-tartrate-hfa-mdi","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Tremor"},{"rate":"5-15","effect":"Nervousness"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Tachycardia"},{"rate":"2-5","effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL3989693","moleculeType":"Small molecule","molecularWeight":"628.72"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levalbuterol is the active R-enantiomer of albuterol that binds to beta-2 adrenergic receptors on airway smooth muscle cells, triggering increased intracellular cAMP and causing bronchodilation. This relieves airway obstruction and improves airflow in patients with obstructive airway diseases. The HFA (hydrofluoroalkane) formulation is a metered-dose inhaler delivery system.","oneSentence":"Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:40.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm in patients with reversible obstructive airway disease"},{"name":"Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT02150499","phase":"PHASE3","title":"A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-07","conditions":"Asthma","enrollment":18},{"nctId":"NCT00809757","phase":"PHASE3","title":"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-12","conditions":"Asthma","enrollment":197},{"nctId":"NCT00909779","phase":"PHASE3","title":"Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT00583986","phase":"PHASE3","title":"Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-09","conditions":"Asthma, Chronic Obstructive Pulmonary Disease, COPD","enrollment":150},{"nctId":"NCT00685347","phase":"PHASE2","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma, Bronchoconstriction","enrollment":33},{"nctId":"NCT00684866","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT00685022","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-06","conditions":"Asthma","enrollment":49},{"nctId":"NCT00684827","phase":"PHASE2","title":"A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma","enrollment":32},{"nctId":"NCT00064389","phase":"PHASE3","title":"Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":746},{"nctId":"NCT00268723","phase":"PHASE3","title":"Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-12","conditions":"Exercise-induced Bronchospasm","enrollment":15},{"nctId":"NCT00685425","phase":"PHASE3","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma, Bronchoconstriction","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xopenex MDI","Xopenex HFA MDI"],"phase":"phase_3","status":"active","brandName":"Levalbuterol tartrate HFA MDI","genericName":"Levalbuterol tartrate HFA MDI","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing. Used for Acute bronchospasm in patients with reversible obstructive airway disease, Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}